Resistance TrainingsIgANCT05221996
Minimal-Dose Resistance Training for Improving sIgA and Cortisol
A study testing Resistance training in people with Resistance Training and Immune System, run by Universidad Francisco de Vitoria at 1 site in Spain.
Trial summary
Whereas the role of endurance training on immune function has been widely studied, little is known about the role of resistance training (RT). In this cross-over randomized controlled study, it will be analysed the effects of three RT protocols which only differs in volume in improving secretory immunoglobulin A… Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Resistance Training, Immune System
- What is being tested?
- Resistance training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteSpain
- Study dates
- 1 Feb 2022to 24 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18-30 years
- Sedentary
Who cannot join
- to have had COVID-19 during the last 3 months
- to have been vaccinated against COVID-19 during the last 3 months
- physical limitations or health problems
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Minimal-Dose Resistance Training for Improving sIgA and Cortisol Among Young, Health and Sedentary People
Whereas the role of endurance training on immune function has been widely studied, little is known about the role of resistance training (RT). In this cross-over randomized controlled study, it will be analysed the effects of three RT protocols which only differs in volume in improving secretory immunoglobulin A (sIgA) and cortisol in saliva among young, health and sedentary people
- Conditions
- Resistance Training, Immune System
- Being tested
- Resistance training
- Keywords
- resistance training, immune system, cortisol
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance trainingBehavioural
Resistance circuit training
| Study group | Role | What they receive |
|---|---|---|
| Resistance exercise for 10 min | Experimental | Resistance circuit training of 10 min Receives: Behavioral: Resistance training |
| Resistance exercise for 20 min | Experimental | Resistance circuit training of 20 min Receives: Behavioral: Resistance training |
| Resistance exercise for 30 min | Experimental | Resistance circuit training of 30 min Receives: Behavioral: Resistance training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of secretory immunoglobulin A (sIgA)
Secretory Immunoglobulin A in saliva
Measured: 2 weeks
Secondary outcomes (1)
Concentration of salivary cortisol (Scortisol)
Cortisol in saliva
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2022
- Study start1 Feb 2022
- Primary completion24 Feb 2022
- Study completion24 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Resistance TrainingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Francisco de Vitoria
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Luis Berlanga, Universidad Francisco de Vitoria
- Investigators
- Luis Berlanga, Principal investigator, Universidad Francisco de Vitoria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05221996
- Sponsor's protocol ID
- UFV2022
- Acronym
- sIgA
- Status last verified
- May 2022
- First submitted
- 2 Feb 2022
- Last updated
- 17 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Minimal-Dose Resistance Training for Improving sIgA and Cortisol Among Young, Health and Sedentary People
- ClinicalTrials.gov ID
- NCT05221996
- Acronym / sponsor ID
- sIgA / UFV2022
- Conditions
- Resistance Training, Immune System
- Keywords
- resistance training, immune system, cortisol
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Universidad Francisco de VitoriaUniversity, hospital or other
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 24 Feb 2022 (actual)
- Study completion
- 24 Mar 2022 (actual)
- First posted
- 3 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Whereas the role of endurance training on immune function has been widely studied, little is known about the role of resistance training (RT). In this cross-over randomized controlled study, it will be analysed the effects of three RT protocols which only differs in volume in improving secretory immunoglobulin A (sIgA) and cortisol in saliva among young, health and sedentary people
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Resistance exercise for 10 min | Experimental | Behavioral: Resistance trainingResistance circuit training of 10 min |
| Resistance exercise for 20 min | Experimental | Behavioral: Resistance trainingResistance circuit training of 20 min |
| Resistance exercise for 30 min | Experimental | Behavioral: Resistance trainingResistance circuit training of 30 min |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 18-30 years
- Sedentary
Key exclusion criteria (3 listed)
- to have had COVID-19 during the last 3 months
- to have been vaccinated against COVID-19 during the last 3 months
- physical limitations or health problems
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance trainingResistance circuit training | Behavioural | Resistance exercise for 10 min, Resistance exercise for 20 min, Resistance exercise for 30 min |
Primary outcome
Concentration of secretory immunoglobulin A (sIgA)
Time frame: 2 weeks
Secretory Immunoglobulin A in saliva
1 secondary outcome
Concentration of salivary cortisol (Scortisol)
Time frame: 2 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 May 2022.
- Individual participant dataSharing planned: No
Related trials for Resistance Training
Not yet recruiting
Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b
Chronic Kidney Disease Stage 3A, Chronic Kidney Disease Stage 3B
Recruiting
Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease
PARKINSON DISEASE (Disorder), Parkinsonism or Parkinson's Disease Nos
RecruitingObservational study
Training Protocol on the Natural History of Tuberculosis
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Enrolling by invitation
Omega-3 Fatty Acids and Muscle Strength
Muscle Strength, Cognitive Function Assessment
Not yet recruiting
Feasibility of Resisted Expiratory Muscle Training for Females Assigned at Birth With Stress Urinary Incontinence: A Pilot Study
Stress Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luis Berlanga principal investigator
Universidad Francisco de Vitoria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance training in people with Resistance Training and Immune System, run by Universidad Francisco de Vitoria at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of secretory immunoglobulin A (sIgA) (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2022.